ISSN 1866-8836
Клеточная терапия и трансплантация

Change template to: announce

Clinical case

A case report of haploidentical hematopoietic stem cell transplantation for diffuse large B-cell lymphoma developing in the course of immunosuppressive therapy after kidney transplantation

Elena N. Parovichnikova, Vera A. Vasilyeva, Olga A. Aleshina, Mariya V. Dovydenko, Larisa A. Kuzmina, Mikhail Yu. Drokov, Irina A. Lukyanova, Vera V. Troitskaya, Evgenii E. Zvonkov, Alla M. Kovrigina, Valery G. Savchenko

Clinical case

A case report of haploidentical hematopoietic stem cell transplantation for diffuse large B-cell lymphoma developing in the course of immunosuppressive therapy after kidney transplantation

Download PDF version

Elena N. Parovichnikova, Vera A. Vasilyeva, Olga A. Aleshina, Mariya V. Dovydenko, Larisa A. Kuzmina, Mikhail Yu. Drokov, Irina A. Lukyanova, Vera V. Troitskaya, Evgenii E. Zvonkov, Alla M. Kovrigina, Valery G. Savchenko

National Medical Research Center for Hematology, Moscow, Russia


Correspondence:
Dr. Vera A. Vasilyeva, PhD, MD, Head Immunochemotherapy Department for BMT patients, National Medical Research Center for Hematology, 4 Novyi Zykovskii Lane, Moscow, 125167, Russia
Phone: +7 (916) 262-23-16
E-mail: vasilievaVA4@mail.ru


Citation: Parovichnikova EN, Vasilyeva VA, Aleshina OA et al. A case report of haploidentical hematopoietic stem cell transplantation for diffuse large B-cell lymphoma developing in the course of immunosuppressive therapy after kidney transplantation. Cell Ther Transplant 2022; 11(1): 50-57.

Post-transplant lymphoproliferative disease (PTLD) is one of the most common complications after organ transplantation. The main goal of PTLD treatment is to achieve stable remission of the disease and preserve the transplanted organ. However, it is not uncommon that after PTLD therapy immunosuppressive therapy for the transplanted organ is returned, which may again lead to a recurrence of PTLD. Autologous hematopoietic stem cell transplantation is a rare option for treatment PTLD. The role of allogeneic hematopoietic stem cell transplantation (HSCT) in PTLD therapy after solid organ transplantation has not been determined, due to the high risks of toxicity for the transplanted organ, the development of a graft-versus-host disease may lead to rejection of the transplanted solid organ, and the presence of a solid organ transplant may increase the rejection of hematopoietic stem cells.

We have described a case report of haploidentical hematopoietic allogeneic stem cell transplantation with TCR αβ+/CD19+ cell depletion for a patient with second remission of diffuse large B-cell lymphoma associated with immunosuppressive therapy for a previously performed allogeneic cadaveric kidney transplantation.

Keywords

Post-transplant lymphoproliferative disease, hematopoietic allogeneic stem cell transplantation, haploidentical, TCR αβ+/CD19+ cell depletion.